Epstein-barr virus nuclear antigen 1 does not cause lymphoma in C57BL/6J mice

Journal of Virology

Volumn 82, Issue 8, 2008, Pages 4180-4183

  Kang, Myung Soo ^a   Soni, Vishal ^a   Bronson, Roderick ^a   Kieff, Elliott ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN; EBV ENCODED NUCLEAR ANTIGEN 1; EBV-ENCODED NUCLEAR ANTIGEN 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; GENE EXPRESSION; INBRED STRAIN; LATENT VIRUS INFECTION; LYMPHOCYTE; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; ANIMAL; C57BL MOUSE; GENETICS; PHYSIOLOGY; VIROLOGY;

HUMAN HERPESVIRUS 4; MUS; MUS MUSCULUS;

ANIMALS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; HERPESVIRUS 4, HUMAN; LYMPHOMA; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC;

EID: 41949087403     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.02596-07     Document Type: Article

References (49)

1. Adams, J. M., A. W. Harris, W. Y. Langdon, C. A. Pinkert, R. L. Brinster, R. D. Palmiter, L. Corcoran, W. S. Alexander, M. W. Graham, and S. Cory. 1986. c-myc-induced lymphomagenesis in transgenic mice and the role of the Pvt-1 locus in lymphoid neoplasia. Curr. Top. Microbiol. Immunol. 132:1-8.
2. Adams, J. M., A. W. Harris, C. A. Pinkert, L. M. Corcoran, W. S. Alexander, S. Cory, R. D. Palmiter, and R. L. Brinster. 1985. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318:533-538.
3. Babbitt, J. T., A. I. Kharazi, J. M. Taylor, C. B. Bonds, S. G. Mirell, E. Frumkin, D. Zhuang, and T. J. Hahn. 2000. Hematopoietic neoplasia in C57BL/6 mice exposed to split-dose ionizing radiation and circularly polarized 60 Hz magnetic fields. Carcinogenesis 21:1379-1389.
4. Babbitt, J. T., A. I. Kharazi, J. M. Taylor, C. B. Bonds, D. Zhuang, S. G. Mirell, E. Frumkin, and T. J. Hahn. 2001. Increased body weight in C57BL/6 female mice after exposure to ionizing radiation or 60Hz magnetic fields. Int. J. Radiat. Biol. 77:875-882.
5. Brooks, L., Q. Y. Yao, A. B. Rickinson, and L. S. Young. 1992. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J. Virol. 66:2689-2697.
6. Chinen, J., and J. M. Puck. 2004. Successes and risks of gene therapy in primary immunodeficiencies. J. Allergy Clin. Immunol. 113:595-603.
7. Cohen, J. I., F. Wang, J. Mannick, and E. Kieff. 1989. Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc. Natl. Acad. Sci. USA 86:9558-9562.
8. Cooper, A., E. Johannsen, S. Maruo, E. Cahir-McFarland, D. Illanes, D. Davidson, and E. Kieff. 2003. EBNA3A association with RBP-Jκ downregulates c-myc and Epstein-Barr virus-transformed lymphoblast growth. J. Virol. 77:999-1010.
9. Cory, S., A. W. Harris, W. Y. Langdon, W. S. Alexander, L. M. Corcoran, R. D. Palmiter, C. A. Pinkert, R. L. Brinster, and J. M. Adams. 1987. The myc oncogene and lymphoid neoplasia: from translocations to transgenic mice. Haematol. Blood Transfus. 31:248-251.
10. Deacon, E. M., G. Pallesen, G. Niedobitek, J. Crocker, L. Brooks, A. B. Rickinson, and L. S. Young. 1993. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J. Exp. Med. 177:339-349.
11. Donsante, A., D. G. Miller, Y. Li, C. Vogler, E. M. Brunt, D. W. Russell, and M. S. Sands. 2007. AAV vector integration sites in mouse hepatocellular carcinoma. Science 317:477.
12. Festing, M. F. 1996. What can gerontologists tell us about the choice of rat strain for toxicological research and screening? Hum. Exp. Toxicol. 15:602-604.
13. Fischer, N., E. Kremmer, G. Lautscham, N. Mueller-Lantzsch, and F. A. Grasser. 1997. Epstein-Barr virus nuclear antigen 1 forms a complex with the nuclear transporter karyopherin α2. J. Biol. Chem. 272:3999-4005.
14. Flavell, J. R., K. R. Baumforth, V. H. Wood, G. L. Davies, W. Wei, G. M. Reynolds, S. Morgan, A. Boyce, G. L. Kelly, L. S. Young, and P. G. Murray. 2008. Down-regulation of the TGF-beta target gene, PTPRK, by the Epstein-Barr virus encoded EBNAl contributes to the growth and survival of Hodgkin's lymphoma cells. Blood 111:292-301.
15. Frappier, L., and M. O'Donnell. 1992. EBNA1 distorts oriP, the Epstein-Barr virus latent replication origin. J. Virol. 66:1786-1790.
16. Frappier, L., and M. O'Donnell. 1991. Epstein-Barr nuclear antigen 1 mediates a DNA loop within the latent replication origin of Epstein-Barr virus. Proc. Natl. Acad. Sci. USA 88:10875-10879.
17. Holowaty, M. N., Y. Sheng, T. Nguyen, C. Arrowsmith, and L. Frappier. 2003. Protein interaction domains of the ubiquitin-specific protease, USP7/HAUSP. J. Biol. Chem. 278:47753-47761.
18. Holowaty, M. N., M. Zeghouf, H. Wu, J. Tellam, V. Athanasopoulos, J. Greenblatt, and L. Frappier. 2003. Protein profiling with Epstein-Barr nuclear antigen-1 reveals an interaction with the herpesvirus-associated ubiquitin-specific protease HAUSP/USP7. J. Biol. Chem. 278:29987-29994.
19. Horner, D., M. Lewis, and P. J. Farrell. 1995. Novel hypotheses for the roles of EBNA-1 and BHRF1 in EBV-related cancers. Intervirology 38:195-205.
20. Hsieh, D. J., S. M. Camiolo, and J. L. Yates. 1993. Constitutive binding of EBNA1 protein to the Epstein-Barr virus replication origin, oriP, with distortion of DNA structure during latent infection. EMBO J. 12:4933-4944.
21. Humme, S., G. Reisbach, R. Feederle, H. J. Delecluse, K. Bousset, W. Hammerschmidt, and A. Schepers. 2003. The EBV nuclear antigen 1 (EBNA1) enhances B cell immortalization several thousandfold. Proc. Natl. Acad. Sci. USA 100:10989-10994.
22. Kang, M. S., S. C. Hung, and E. Kieff. 2001. Epstein-Barr virus nuclear antigen 1 activates transcription from episomal but not integrated DNA and does not alter lymphocyte growth. Proc. Natl. Acad. Sci. USA 98:15233-15238.
23. Kang, M. S., H. Lu, T. Yasui, A. Sharpe, H. Warren, E. Cahir-McFarland, R. Bronson, S. C. Hung, and E. Kieff. 2005. Epstein-Barr virus nuclear antigen 1 does not induce lymphoma in transgenic FVB mice. Proc. Natl. Acad. Sci. USA 102:820-825.
24. Kaye, K. M., K. M. Izumi, and E. Kieff. 1993. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc. Natl. Acad. Sci. USA 90:9150-9154.
25. Kennedy, G., J. Komano, and B. Sugden. 2003. Epstein-Barr virus provides a survival factor to Burkitt's lymphomas. Proc. Natl. Acad. Sci. USA 100:14269-14274.
26. Kennedy, G., and B. Sugden. 2003. EBNA-1, a bifunctional transcriptional activator. Mol. Cell. Biol. 23:6901-6908.
27. Kieff, E., and A. B. Rickinson. 2001. Epstein-Barr virus and its replication, p. 2511-2574. In D. M. Knipe and P. M. Howley (ed.), Fields virology, 4th ed., vol. 2. Lippincott Williams and Wilkins, Philadelphia, PA.
28. Komano, J., S. Maruo, K. Kurozumi, T. Oda, and K. Takada. 1999. Oncogenic role of Epstein-Barr virus-encoded RNAs in Burkitt's lymphoma cell line Akata. J. Virol. 73:9827-9831.
29. Komano, J., M. Sugiura, and K. Takada. 1998. Epstein-Barr virus contributes to the malignant phenotype and to apoptosis resistance in Burkitt's lymphoma cell line Akata. J. Virol. 72:9150-9156.
30. Mahler, J. F., W. Stokes, P. C. Mann, M. Takaoka, and R. R. Maronpot. 1996. Spontaneous lesions in aging FVB/N mice. Toxicol. Pathol. 24:710-716.
31. Maruo, S., E. Johannsen, D. Illanes, A. Cooper, and E. Kieff. 2003. Epstein-Barr virus nuclear protein EBNA3A is critical for maintaining lymphoblastoid cell line growth. J. Virol. 77:10437-10447.
32. Middleton, T., and B. Sugden. 1992. EBNA1 can link the enhancer element to the initiator element of the Epstein-Barr virus plasmid origin of DNA replication. J. Virol. 66:489-495.
33. Nienhuis, A. W., C. E. Dunbar, and B. P. Sorrentino. 2006. Genotoxicity of retroviral integration in hematopoietic cells. Mol. Ther. 13:1031-1049.
34. Oudejans, J. J., D. F. Dukers, N. M. Jiwa, A. J. van den Brule, F. A. Grasser, P. C. de Bruin, A. Horstman, W. Vos, J. van Gorp, J. M. Middeldorp, and C. J. Meijer. 1996. Expression of Epstein-Barr virus encoded nuclear antigen 1 in benign and malignant tissues harbouring EBV. J. Clin. Pathol. 49:897-902.
35. Rawlins, D. R., G. Milman, S. D. Hayward, and G. S. Hayward. 1985. Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region. Cell 42:859-868.
36. Robertson, E. S., S. Grossman, E. Johannsen, C. Miller, J. Lin, B. Tomkinson, and E. Kieff. 1995. Epstein-Barr virus nuclear protein 3C modulates transcription through interaction with the sequence-specific DNA-binding protein J. kappa. J. Virol. 69:3108-3116.
37. Rodriguez-Cuesta, J., F. Vidal-Vanaclocha, L. Mendoza, M. Valcarcel, N. Gallot, and G. Martinez de Tejada. 2005. Effect of asymptomatic natural infections due to common mouse pathogens on the metastatic progression of B16 murine melanoma in C57BL/6 mice. Clin. Exp. Metastasis 22:549-558.
38. Ruf, I. K., P. W. Rhyne, C. Yang, J. L. Cleveland, and J. T. Sample. 2000. Epstein-Barr virus small RNAs potentiate tumorigenicity of Burkitt lymphoma cells independently of an effect on apoptosis. J. Virol. 74:10223-10228.
39. Ruf, I. K., P. W. Rhyne, H. Yang, C. M. Borza, L. M. Hutt-Fletcher, J. L. Cleveland, and J. T. Sample. 1999. Epstein-Barr virus regulates c-Myc, apoptosis, and tumorigenicity in Burkitt lymphoma. Mol. Cell. Biol. 19:1651-1660.
40. Saridakis, V., Y. Sheng, F. Sarkari, M. N. Holowaty, K. Shire, T. Nguyen, R. G. Zhang, J. Liao, W. Lee, A. M. Edwards, C. H. Arrowsmith, and L. Frappier. 2005. Structure of the p53 binding domain of HAUSP/USP7 bound to Epstein-Barr nuclear antigen 1: implications for EBV-mediated immortalization. Mol. Cell 18:25-36.
41. Schmidt, E. V., P. K. Pattengale, L. Weir, and P. Leder. 1988. Transgenic mice bearing the human c-myc gene activated by an immunoglobulin enhancer: a pre-B-cell lymphoma model. Proc. Natl. Acad. Sci. USA 85:6047-6051.
42. Shimizu, N., A. Tanabe-Tochikura, Y. Kuroiwa, and K. Takada. 1994. Isolation of Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV. J. Virol. 68:6069-6073.
43. Themis, M., S. N. Waddington, M. Schmidt, C. von Kalle, Y. Wang, F. Al-Allaf, L. G. Gregory, M. Nivsarkar, M. V. Holder, S. M. Buckley, N. Dighe, A. T. Ruthe, A. Mistry, B. Bigger, A. Rahim, T. H. Nguyen, D. Trono, A. J. Thrasher, and C. Coutelle. 2005. Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice. Mol. Ther. 12:763-771.
44. Tsimbouri, P., M. E. Drotar, J. L. Coy, and J. B. Wilson. 2002. bcl-xL and RAG genes are induced and the response to IL-2 enhanced in EmuEBNA-1 transgenic mouse lymphocytes. Oncogene 21:5182-5187.
45. Vaux, D. L., S. Cory, and J. M. Adams. 1988. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335:440-442.
46. Wang, Y., J. E. Finan, J. M. Middeldorp, and S. D. Hayward. 1997. P32/TAP, a cellular protein that interacts with EBNA-1 of Epstein-Barr virus. Virology 236:18-29.
47. Wilson, J. B., J. L. Bell, and A. J. Levine. 1996. Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. EMBO J. 15:3117-3126.
48. Wood, V. H., J. D. O'Neil, W. Wei, S. E. Stewart, C. W. Dawson, and L. S. Young. 2007. Epstein-Barr virus-encoded EBNA1 regulates cellular gene transcription and modulates the STAT1 and TGFβ signaling pathways. Oncogene 26:4135-4147.
49. Wysokenski, D. A., and J. L. Yates. 1989. Multiple EBNA1-binding sites are required to form an EBNA1-dependent enhancer and to activate a minimal replicative origin within oriP of Epstein-Barr virus. J. Virol. 63:2657-2666.